Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lisata Therapeutics ( (LSTA) ) has shared an announcement.
On June 10, 2025, Lisata Therapeutics, Inc. held its Annual Meeting of Stockholders where five key proposals were approved. The stockholders re-elected two directors, approved an amendment to increase shares in the Employee Stock Purchase Plan, ratified the appointment of Grant Thornton LLP as the accounting firm for 2025, and approved executive compensation and its annual advisory vote frequency.
The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.
Spark’s Take on LSTA Stock
According to Spark, TipRanks’ AI Analyst, LSTA is a Neutral.
Lisata Therapeutics is navigating through financial difficulties with persistent losses and negative cash flows. The stock’s technical indicators and valuation reflect a challenging financial position. However, recent advancements in clinical trials and regulatory achievements offer potential upside, albeit with high risk.
To see Spark’s full report on LSTA stock, click here.
More about Lisata Therapeutics
Average Trading Volume: 12,759
Technical Sentiment Signal: Sell
Current Market Cap: $23.13M
For a thorough assessment of LSTA stock, go to TipRanks’ Stock Analysis page.